The General Court held that the respective pharma products were merely similar, not (as the Board of Appeal had found) highly similar. However, there was a high level of visual and phonetic similarity between the marks and that, since neither word meant anything to the relevant Italian public, the marks were highly similar. The fact that the relevant public might display a high level of attention was insufficient to exclude a likelihood of confusion between the marks.